Science

Pipeline

Oncology Venture Pipeline

Pipeline Overview

pipeline

LiPlaCis

Enables a more selective up-take of cisplatin at the tumor site

LiPlaCis® is an intelligent, target controlled liposome formulation of one of the world’s most widely used chemotherapeutic agents, cisplatin, which has documented efficacy in numerous tumor types.

The specific LiPlaCis formulation allows delivery of LiPlaCis directly to the tumor site where is it needed.

2X-121

2X-121 has a novel dual-inhibitory action against both PARP 1/2 and Tankyrase 1/2
2X-121 is an investigational, orally-available small molecule targeted inhibitor of Poly ADP ribose polymerase (PARP), a key enzyme involved in DNA damage repair in cancer cells.

Dovitinib

Dovitinib is an investigational orally active small molecule multi-kinase inhibitor that exhibits potent activity against multiple RTKs involved in tumor growth and angiogenesis.

Dovitinib binds to and inhibits the phosphorylation of type III-V RTKs, such as vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) that promote tumor cell proliferation and survival in certain cancer cells.

2X-111

Glutathione-enhanced, PEGylated Liposomal Doxorubicin

This novel drug candidate is designed for the liposomal delivery of the anti-cancer drug doxorubicin directly to a tumor, with a glutathione coating added to exploit active endogenous transporters, allowing the drug to cross the blood-brain barrier. 

Irofulven

This drug candidate is a synthetic drug candidate based on a naturally occurring substance that exploits a deficiency in the DNA repair mechanism of cancer cells in a manner similar to a PARP inhibitor.

Irofulven alkylates DNA and protein macromolecules, forms adducts, and arrests cells in the S-phase of the cell cycle. This agent requires NADPH-dependent metabolism by alkenal/one oxidoreductase for activity.

APO010

APO010 is a novel, investigational systemic chemotherapeutic treatment targeting multiple myeloma, a systemic malignancy in the blood that affects plasma cells.

The human immune system can kill cancer cells using a certain type of white blood cells called cytotoxic T lymphocytes (CTLs). One way CTLs kill cancer cells is programmed cell death (apoptosis). A Fas ligand (FasL) on the CTL binds to a death receptor (CD95) on the target cell. This triggers apoptosis.